TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06022861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY01015
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, thereafter, 480mg every 4 weeks(Q4W) during the maintenance treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Intravenouslly (IV) l 800mg/m2 every 4 weeks (（on Day 1 through Day 5)during the combined chemotherapy period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Intravenouslly (IV) 80mg/m2 every 4 weeks (Q4W) during the combined chemotherapy period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opdivo®
Description: Intravenouslly (IV) 240mg every 2 weeks (Q2W) during the combined chemotherapy period, 480mg every 4 weeks(Q4W) during the maintenance treatment period within 24 weeks, thereafter converted to LY01015 480mg every 4 weeks(Q4W).
Study: NCT06204965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Time-restricted eating (TRE) is a dietary pattern where food intake is restricted to 8 hours of the day with no limitation on nutrient quality or quantity. Participants assigned to the intervention group will eat their usual diet from 9:00 a.m. to 5:00 p.m., and then fast until the next day (protocol 8/16). During the 16-hour fast, only hot and cold drinks will be allowed, i.e. coffee, tea or tea and water, but all products and dishes with energy value (including coffee cream, sweet teas, alcohol, snacks, etc.) will be prohibited. The TRE protocol will be implemented 7 days a week for a period of 3 months (12 weeks).
Study: NCT04942574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
Study: NCT06562205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Study: NCT04742491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Truvada in the US
Description: Truvada in the United States

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Truvada in the US
Description: Truvada in the United States

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Truvada in Brazil
Description: Truvada in Brazil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Truvada in Brazil
Description: Truvada in Brazil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Intervention Arm Descovy in the US
Description: Descovy in the United States

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred Intervention Arm Descovy in the US
Description: Descovy in the United States
Study: NCT05872737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB)
Description: The Facilitator-guided Acceptance and Commitment Bibliotherapy (FAB) is a 12-week self-help parenting program that integrates Acceptance and Commitment Therapy (ACT) principles with web-based modules and group-based sessions. The program includes a self-help workbook/manual and ACT protocols that cover various self-help exercises such as guided imagery, grounding, mindfulness, and values clarifications. To make the programme more relatable to Hong Kong parents caring for children with NDD, storytelling vignettes and therapeutic narratives will be included. Parents will work on each module at their own pace within 2-3 weeks and meet with trained facilitators in a video-conferencing format after completing each module to review their progress and learn positive parenting techniques.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General Parenting Education and Advice
Description: Both the FAB group and the Control Group will receive routine family support services from collaborating NGOs, including education on managing the emotional and behavioral symptoms of children with NDD. To control for the interaction/social effect present in the FAB group, the Control Group will also receive four video-conferencing sessions guided by a trained research assistant over 12 weeks. These sessions will facilitate parents to discuss their parenting challenges, identify parenting traps, and provide general parenting advice as recommended by the Child Assessment Services, Department of Health under the HKSAR government.
Study: NCT06203054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penditure™ Left Atrial Appendage (LAA) Exclusion System
Description: Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
Study: NCT06027580

Intervention type: DEVICE
Intervention: SPIO® Core-MAX® Expedition thoracolumbosacral orthosis
Description: SPIO® Core-MAX® Expedition thoracolumbosacral orthosis use 2 hours per day for 6 months

Intervention type: OTHER
Intervention: Standard Care Therapy option
Description: Standard of care Therapy without the use of trunk orthosis
Study: NCT04914364

Intervention type: OTHER
Intervention: Balance assessments
Description: There is no formal intervention in this study. The investigators will only be completing balance assessments with no follow-up visit.
Study: NCT05635461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: 150 mg of either tablet or suspension formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: 150 mg of either tablet or suspension formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVN424
Description: 150 mg of either tablet or suspension formulation
Study: NCT04797611

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-invasive brainstem stimulation
Description: Study participants will self-administer \~19-minute treatments twice daily in the home setting over 12 weeks using a non-invasive brainstem modulation device. The device has been deemed to be a nonsignificant risk for studies in Parkinson's disease by the United States Food and Drug Administration.
Study: NCT05993689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BUNDLE
Description: An integrated model of community-based doulas and clinical obstetric providers

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard of care for pregnancy and pregnancy-related issues by the obstetric provider
Study: NCT05758168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Addition of Tie-Over Bolster Dressing
Description: Bolster will be sutured into place using peripheral non-absorbable anchoring sutures.
Study: NCT04031105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% or 100%\* resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)~\*The optimal %RMT will be evaluated in a pilot study before commencement of the main study
Study: NCT05615376

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECG application
Description: The app together with the wearable device will record a V1 (Left wrist) or V2 (left ankle) ECG reading. These measurements will be conducted on Day 1 and Day 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12 lead ECG
Description: The 12 lead ECG will measure corrected QT interval by recording RR and QT intervals on Day 1 and Day 4. This will be performed within the same episode of care as the wearable device ECG recording. There is no need to perform both at exactly the same time point, but within a 15 minute window.
Study: NCT06527469

Intervention type: OTHER
Intervention: PhysZou emPOWER: a strength, power, and gait intervention group physical therapy program for children with CP
Description: Each session will include a 10-minute game-based warm-up, 45 minutes of gait interventions to include treadmill and overground walking as well as other aerobic activities, 45 minutes of resistance training (power and strength training as appropriate for their individual goals), and a 10-minute cool-down incorporating yoga and breathing activities. To ensure participants are exercising at the appropriate level of intensity, 1 repetition maximum measures will be used to determine the appropriate levels of resistance and heart rate monitors will be worn.
Study: NCT04239911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth app
Description: The mHealth app will provide heart failure-specific education to home health aides and allow them to report clinical observations and ask nurses questions in real-time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual training course
Description: Virtual training course on heart failure for home health aides.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual training course
Description: Virtual training course on heart failure for home health aides.
Study: NCT06564389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07832837
Description: escalated doses of PF-07832837

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05068752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily
Study: NCT05743868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Dinner
Description: De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Dinner
Description: De novo lipogenesis (DNL) will be assessed in all participants with a standardized dinner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Premeal exercise
Description: DNL will be assessed in all participants with short bouts of premeal exercise with a standardized dinner
Study: NCT05911984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3811 Injection
Description: Intravenous injection
Study: NCT04827368

Intervention type: OTHER
Intervention: Breath Test
Description: Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.

Intervention type: OTHER
Intervention: Breath Test
Description: Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.

Intervention type: OTHER
Intervention: Breath Test
Description: Research Breath sample through disposable mouth filter. Serum sample through routine blood draw. Stool sample through standard collection containers.
Study: NCT05772390

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast re-irradiation
Description: partial breast re-irradiation
Study: NCT06226090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 7.5 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 7.5 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Dose is 7.5mg once a week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 15 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 15 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 22.5 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 22.5 mg
Description: Subcutaneous injections with calorie-restricted diet and increased physical activity for 24 weeks. Doses gradually increased from 7.5 mg to 22.5 mg.
Study: NCT06277739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Therapy
Description: The participant was placed in a side-lying position facing the clinician with the more painful side facing upward. The clinician passively flexed the participant's hips and knees to induce lumbar spine flexion until they felt the spinous process of the affected lumbar vertebrae begin to move. Next, the clinician passively rotated the participant's torso opposite to the side they were lying on until they felt rotation in the vertebra above the suspected lesion. The clinician applied a rapid thrust to the shoulder (anterior to posterior force) and pelvis (posterior to anterior force) resulting in a rotation force couple on the hypomobile segment. If a cavitation (ie, an audible pop) occurred, the treatment was considered complete. If no cavitation was produced, the participant was repositioned and the manipulation was attempted again. A maximum of 2 attempts per side was permitted. If no cavitation was produced after the 4 attempts (ie, 2 per side), the treatment was considered complete.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Laser Treatment
Description: The laser manufacturer (MedX Health Corp) provided a MedX 1100 system that did not deliver any significant amount of light energy or heat but otherwise appeared operational to participants and clinicians. The sham laser was delivered over the painful region with the study participant positioned as described for spinal manipulation and spinal mobilization treatments.
Study: NCT05101317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115
Description: HMI-115 is human monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115
Description: HMI-115 is human monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115
Description: HMI-115 is human monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05849454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Messy Memories Intervention
Description: Messy Memories is a mobile application that allows users to self-administer exposure therapy techniques outside of the traditional psychotherapy context. Participants are asked to audio record a difficult (messy) memory, including what they did, felt, thought, smelled, saw, etc. They are then asked questions about what it was like to re-experience the memory, such as what emotions were elicited (e.g., sadness, anger, fear). Next, participants are asked to process what the memory means to them. They are then instructed to listen to their recording as often as they like, until the memory becomes easier to re-experience. They respond to processing questions each time they listen to their prior difficult memory.
Study: NCT05003401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabitAware Keen2
Description: Participants will receive an awareness bracelet to be worn on the dominant wrist over a period of 4 weeks. The bracelet device will vibrate when the participant is engaging in hair pulling behaviors. As hair pulling behaviors may occur outside of awareness (i.e., automatic pulling behaviors), this vibration and detection is anticipated to increase the participants awareness of hair pulling behaviors.
Study: NCT05418816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SelfWrap Bioabsorbable Perivascular Wrap
Description: SelfWrap is applied during the normal arteriovenous fistula (AVF) creation procedure. It provides mechanical support to the vein and induces outward remodeling to improve maturation and patency of AVFs.
Study: NCT05519241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLZ4-coated paclitaxel-loaded micelles (PPM)
Description: PPM will be administrated weekly for 6 times through intravesical instillation into the bladder cavity
Study: NCT05883501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation versus back massage
Description: Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-affirmation versus back massage
Description: Self-affirmation is non-pharmacological intervention which represents structured sentences to convey to the subconscious mind to help in reprogramming negative thoughts into positive ones.~Massage is defined as systematic touch of soft tissues for therapeutic purposes, such as pain relief, increased comfort and patient's relaxation
Study: NCT06062290

Intervention type: DEVICE
Intervention: Electromyography (EMG)
Description: Measurement of the compound muscle action potential for the assessment of neuromuscular function

Intervention type: DEVICE
Intervention: Electromyography (EMG)
Description: Measurement of the compound muscle action potential for the assessment of neuromuscular function
Study: NCT06360380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaPass System
Description: a treatment session of up to 5 hours with the AquaPass system, evaluating net fluid removal for efficacy analysis and effect on vital signs for safety analysis
Study: NCT05107336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Participants will receive subcutaneous injection of AZD2693, once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Participants will receive subcutaneous injection of AZD2693, once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Participants will receive subcutaneous injection of AZD2693, once per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2693
Description: Participants will receive subcutaneous injection of AZD2693, once per month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive subcutaneous injection of placebo (volume matching to AZD2693 injection \[0.9% saline solution\]), once per month.
Study: NCT05301660

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine transdermal patch
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Description: 14 mg / tablet, one tablet a day, attached to the patient's back for 8 weeks
Study: NCT05775367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: A cochlear implant is a surgically implanted device that provides access to sound in people cannot get enough access to sound for communication with traditional hearing aids.
Study: NCT05916183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid loss and consumption
Description: Upon 5% body mass loss, rehydration of fluid lost to sweating throughout a 2 hour recovery period